<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497325</url>
  </required_header>
  <id_info>
    <org_study_id>ASUM hospital</org_study_id>
    <nct_id>NCT03497325</nct_id>
  </id_info>
  <brief_title>Effect of Autologous Platelet-rich Plasma in Uterine Wound Healing</brief_title>
  <official_title>the Efficacy of Intramuscular Autologous Platelet-rich Plasma Injection on Uterine Wound Healing After Primary Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of intramuscular autologus platelet rich
      plasma on uterine wound healing after primary cesarean section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      110 pregnant female undergoing primary prelabor CS will be randomized to two groups group
      A)autologus PRP will be prepared from participant venous blood collected from the
      participants' arm into a syringe primed with ACD-A. then it will be injected into uterus
      after closing uterine incision . Injection sites will be selected near the incision at evenly
      20 different sites

      group B)normal saline 0.9 will be injected into uterus after closing uterine incision .
      Injection sites will be selected near the incision at evenly 20 different sites.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of cesarean scar defect(niche)</measure>
    <time_frame>6 weeks after CS</time_frame>
    <description>any defect in the anterior myometrium related to scar site</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologus platelet rich plasma</intervention_name>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision</description>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term pregnancy (gestational age between 37-41 weeks).

          -  Women undergoing cesarean section for the first time.

          -  Normal vaginal ultrasound examination and exclusion of any pelvic abnormality.

          -  Uncomplicated cesarean section.

          -  Lower uterine segment cesarean sections while the women not in labor

        Exclusion Criteria:

          -  Women with complications during or after cesarean section as intrapartum or postpartum
             hemorrhage, puerperal sepsis, septic wound

          -  Women with medical diseases that can affect the healing as diabetes mellitus, anemia,
             chronic renal disease or hepatic disease or coagulopathy or receiving medications
             affect wound healing as corticosteroids or anticoagulant.

          -  Women who will use intrauterine device as a contraceptive method Women with uterine
             abnormality as cervical stenosis or fibroid uterus multiple gestation, placenta
             abruption, placenta previa, antepartum hemorrhage prolonged ROM,
             chorioamnionitis,meconium stained liquor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Rasheedy Ali</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

